GlaxoSmithKline's shingles vaccine 'Shingrix' took the lead in Korea’s market just 7 months after its release. With its powerful shingles prevention effect, its sales surpassed that of its competitors. SkYZoster, a homegrown vaccine, had taken the lead in the market for the first time at the end of last year but was overtaken by Shingrix in just 2 quarters.

According to the market research institution IQVIA on the 26th, the market for preventive vaccines for shingles was KRW 45.4 billion in 1H last year, which was a 123.3% increase from the KRW 20.4 billion in 1H last year. The shingles vaccine market grew 147.0% YoY to record KRW 21.9 billion in Q1 this year, then again rose 124.1% to KRW 23.5 billion.